AZ’s Alexion looks to hold off Big Pharma challengers

Today's Big News

Dec 16, 2022

After prior rejection, Ferring finally nabs FDA nod for bladder cancer gene therapy


AstraZeneca's Alexion hopes to extend dominance in PNH as Big Pharma competitors close in


Centene taps new president, COO amid slew of leadership changes


Siemens, GE considering buying up Medtronic segments slated for spinout: Bloomberg


In surprise move, AbbVie bows out of top industry groups


'The Top Line': The medtech industry’s highest paid CEOs, plus this week's headlines

 

Featured

After prior rejection, Ferring finally nabs FDA nod for bladder cancer gene therapy

With its second approval in as many months, Ferring Pharmaceuticals is celebrating a fruitful end to 2022. 
 

Top Stories

AstraZeneca's Alexion hopes to extend dominance in PNH as Big Pharma competitors close in

For years, Alexion has been the only name in the game for a blood disease called paroxysmal nocturnal hemoglobinuria. Now, a number of Big Pharmas want in.

Centene taps new president, COO amid slew of leadership changes

Centene CEO Sarah London is continuing to build out the insurer's leadership team. London was tapped to succeed longtime CEO Michael Neidorff in March.

Siemens, GE considering buying up Medtronic segments slated for spinout: Bloomberg

Medtronic laid out the plans to spin off its patient monitoring and respiratory interventions businesses into a combined company in late October.

In surprise move, AbbVie bows out of top industry groups

Top industry trade groups will be continuing on without pharma powerhouse AbbVie. The company quietly departed from the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Innovation Organization (BIO), plus the Business Roundtable, Politico first reported.

'The Top Line': The medtech industry’s highest paid CEOs, plus this week's headlines

This week on “The Top Line,” we discuss the medtech industry’s highest paid CEOs. Plus, we cover Theranos' COO's prison sentence, highlights from the American Society of Hematology annual meeting and other top headlines from this week.

MedCognetics scores FDA green light for breast cancer screening AI

The QmTriage software takes in standard 2D mammograms to look for potential signs of cancer. If any are found, the system labels them and automatically flags the scan for closer review by a human radiologist.

Alnylam culls 3 programs, including nephropathy med that was slated for ph. 3

Alnylam has elected to cull three clinical-stage programs, including an IgA nephropathy med once-partnered with Regeneron that was headed for a phase 3 trial. Alnylam said that Regeneron pulled out of the program, prompting a reassessment of development plans.

Robot bringing companionship to seniors, ElliQ, gets 2.0 update including caregiver app

ElliQ, the first proactive AI care companion and Time Best Invention of 2022, is getting an update with 2.0 hardware and software along with the new addition of a caregiver app in order to further address the senior loneliness epidemic.

Astellas' 2nd phase 3 win in a month for cancer antibody tees up submissions to regulators

If Astellas needed further proof that its $1.3 billion oncology bet was worth the price tag, the second successful phase 3 trial in a month should do the trick.

Lilly pens $730M biobucks deal with Sosei Heptares to get in on GPCR action

Eli Lilly has followed in the footsteps of many Big Pharma contemporaries by penning its own $730 million deal with Sosei Heptares to work on new meds that modulate G protein-coupled receptor (GPCR) targets.

At least 24 hospitals, providers have been targeted online and offline over gender-affirming care, report says

"Inflammatory" posts from influential social media users regularly escalate to offline threats that are forcing providers to limit gender-affirming services or resources, according to a new report from an LGBTQ+ civil rights organization.

AZ wins patent fight with Viatris, gains more exclusivity for blockbuster Symbicort

A federal court in West Virginia has upheld AstraZeneca's claim of infringement against Viatris and Kindeva. With the win, AZ gains six more months of exclusivity for asthma inhaler Symbicort, which generated (PDF) $2.7 billion in sales in 2021.
 
Fierce podcasts

Don't miss an episode

'The Top Line': Medtech's highest paid CEOs, this week's news

This week on “The Top Line,” we discuss the medtech industry’s highest paid CEOs. Plus, we cover Theranos' COO's prison sentence, highlights from the American Society of Hematology annual meeting and other top headlines from this week.

 

Resources

Video

Discover the future of mAb manufacturing

Revolutionize your monoclonal antibody (mAb) manufacturing with expert insights.
Whitepaper

Enhance the cost-effectiveness of your chemical supply chain

Learn how to develop a high-performing supply chain for GMP-manufactured chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific.
Whitepaper

Plan for scalable process liquid and buffer preparation

Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation.
Webinar

Webinar: Writing the Future of Antibody Discovery Solutions

Twist Bioscience CSO Dr. Aaron Sato shares how Twist's tools for antibody discovery have been applied to identify antibodies against diverse and challenging targets. See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions.

Executive Summary

Scale-Up Strategies for Late-Stage Cell Therapies

Strategies to help scale-up for commercial manufacturing are critical to getting cell and gene therapies to patients as more advanced therapies reach late-stage clinical studies and regulatory decisions.

Whitepaper

Lipid-Based Drug Delivery System to Bring Poorly Soluble Drugs to Market

How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market?
Whitepaper

Linear Compression vs. Parallel Processing: Speeding Biologics Through Development and Into Clinical Trials

Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more.

Whitepaper

Intranasal Drug Product Development: Formulation to Manufacturing

What are key considerations for intranasal delivery in the treatment of acute and chronic conditions?
Whitepaper

Formulation Strategies When Transitioning From Vial to PFS

Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.
Research

A Strategy to Standardize Process Characterization & Late Phase Development

Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments.

Whitepaper

Supply Services to Support Clinical Trials in Japan & Beyond

Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world.
Whitepaper

Clinical Supply Solutions for the Asia-Pacific Region

Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region.
 

Industry Events

 

Upcoming Fierce Events

10
Jan
San Francisco, CA
17-19
Jan
Virtual Event
27-28
Feb
Arlington, VA
14-15
Mar
San Francisco, CA
20-22
Mar
West Palm Beach, FL

View all events